Fig. 1From: Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trialPatient disposition during the placebo-controlled and open-label extension periods of the ASCEND trialBack to article page